Results 301 to 310 of about 182,387 (331)
Some of the next articles are maybe not open access.
Angiozyme: A Novel angiogenesis inhibitor
Current Oncology Reports, 2001Several inhibitors of angiogenesis are being developed for the treatment of cancer. One dominant strategy involves disruption of the vascular endothelial growth factor (VEGF) pathway by inhibition of the receptors for VEGF. Inhibition of the VEGF receptor activity can be accomplished using catalytic RNA molecules known as ribozymes, which downregulate ...
David E. Weng, Nassim Usman
openaire +3 more sources
Novel benzoxazines as inhibitors of angiogenesis
Investigational New Drugs, 2014Dysregulation of angiogenesis has been associated with many pathological disorders, including cancer; where angiogenesis has been found to be critical for the maintenance and metastasis of tumours. One of the pathways involved in the regulation of angiogenesis is the phosphatidylinositol3-kinase (PI3K) signalling pathway.
Sara Al-Rawi +3 more
openaire +3 more sources
Angiogenesis and angiogenesis inhibitors in cancer.
Forum (Genoa, Italy), 1999Angiogenesis, the development of a new blood supply, is an essential process of tumour growth and metastasis. Over the past few years, this has led to the consideration of the tumour vasculature as an optimal target for anti-cancer strategies. The process of angiogenesis consists of a series of interactive events: quiescent endothelial cells are ...
R, Giavazzi, G, Taraboletti
openaire +1 more source
Investigational Angiogenesis Inhibitors
2010Targeting angiogenesis is an evolving field of cancer research. Tumor angiogenesis is considered as an important step in the progression and metastasis of prostate cancer. Several pathways that converge toward promotion of growth, proliferation, and survival of prostate cancer cells have been targeted, including modulation of proangiogenic factors such
William Dahut, Jeanny B. Aragon-Ching
openaire +2 more sources
Resistance to Inhibitors of Angiogenesis
2018Angiogenesis, a process that is predominantly driven by the vascular endothelial growth factor (VEGF) signaling pathway, plays an essential role in tumor progression and metastasis. Accordingly, a range of anti-angiogenic agents, most of which block VEGF or its receptor, have been approved for the treatment of various malignant diseases.
Ksenia Magidey, Yuval Shaked, Nili Dahan
openaire +2 more sources
Update on Endogenous Inhibitors of Angiogenesis
Endothelium, 2006Angiogenesis is regulated by a local balance between the levels of endogenous stimulators and inhibitors of angiogenesis. Understanding of the mechanism of angiogenesis has advanced significantly since the discovery of two members of the family of angiogenesis stimulators, i.e., vascular endothelial growth factor family proteins and angiopoietins ...
openaire +3 more sources
The preclinical evaluation of angiogenesis inhibitors
Investigational New Drugs, 1997Angiogenesis is a fundamental process which is required for a number of physiological and pathophysiological processes. The field of angiogenesis therefore has many therapeutic implications and has progressed rapidly. Many strategies have been devised to regulate angiogenesis and several endogenous and synthetic inhibitors of angiogenesis have now been
openaire +3 more sources
Inhibitors of Tumor Angiogenesis
2010Tumor growth relies on formation of a vascular supply. In 1971, Judah Folkman was the first to propose that in order to grow beyond 2–3 mm in size tumors required a new vascular network [16]. Subsequent research has confirmed that growth of a tumor, both at the primary site and metastases, is dependent on neoangiogenesis [17, 24]. This development of a
Anaadriana Zakarija +1 more
openaire +2 more sources